Velaglucerasa alfa (VPRIV)

Covered only for the FDA‑approved indication of Type 1 Gaucher disease (other indications excluded). Approval is for 1 year at 60 U/kg IV no more frequently than every 2 weeks and requires documentation of deficient β‑glucocerebrosidase activity OR glucocerebrosidase gene mutation and that the drug is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or lysosomal storage disorder specialist.

"Vpriv is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.